DrugPatentWatch Database Preview

XYREM Drug Profile

« Back to Dashboard

When do Xyrem patents expire, and when can generic versions of Xyrem launch?

Xyrem is a drug marketed by Jazz Pharms and is included in one NDA. There are eighteen patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in XYREM is sodium oxybate. There are one thousand four hundred and fifty-four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sodium oxybate profile page.

Summary for XYREM

US Patents:	18
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	16
Patent Applications:	4,351
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for XYREM
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XYREM
DailyMed Link:	XYREM at DailyMed

Pharmacology for XYREM

Drug Class	Central Nervous System Depressant
Physiological Effect	Central Nervous System Depression Decreased Central Nervous System Organized Electrical Activity

Medical Subject Heading (MeSH) Categories for XYREM

Adjuvants, Anesthesia

Anesthetics, Intravenous

Synonyms for XYREM

.Gamma.-Hydroxy butyrate

.gamma.-Hydroxy sodium butyrate

.gamma.-Hydroxybutyrate sodium

.gamma.-Hydroxybutyric acid decomposition product

.gamma.-Hydroxybutyric acid monosodium salt

.gamma.-Hydroxybutyric acid, sodium salt

.gamma.-OH

3-carboxypropoxy acid

30470-15-6

30IW36W5B2

4 HB

4-03-00-00774 (Beilstein Handbook Reference)

4-hydroxy-butanoic acid

4-hydroxy-butyric acid

4-Hydroxyacid

4-Hydroxyalkanoic acid

4-Hydroxybutanoic acid

4-Hydroxybutanoic acid #

4-Hydroxybuttersaeure

4-Hydroxybutyrate sodium

4-Hydroxybutyric acid

4-Hydroxybutyric acid monosodium salt

4-Hydroxybutyric acid sodium salt

4-Hydroxycarboxylic acid

4-OHB

52352-27-9

591-81-1

AA3E2AF0-AB7A-4A1E-A391-199C049D7162

AC1L1V58

AKOS022632618

Alcover

AN-8743

Anetamin

BDBM50023575

BRN 1720582

Butanoic acid, 4-hydroxy-

Butanoic acid, 4-hydroxy-, sodium salt

Butanoic acid,4-(1-oxobutoxy)-

Butyric acid, 4-hydroxy-

Butyric acid, 4-hydroxy-, monosodium salt

BUTYRIC ACID, 4-HYDROXY-, SODIUM SALT

C00989

C01991

C4H8O3

CHEBI:30830

CHEMBL1342

CTK4G5262

D0EP8X

DEA No. 2010

DTXSID2074740

EB 27

Gam-OH

Gamma Hydroxybutyric Acid

Gamma OH

gamma-hydroxy butyrate

gamma-Hydroxy sodium butyrate

gamma-Hydroxybutanoic acid

gamma-Hydroxybutyrate

gamma-Hydroxybutyrate sodium

gamma-Hydroxybutyric acid

gamma-Hydroxybutyric acid decomposition product

Gamma-Hydroxybutyric acid monosodium salt

Gamma-OH

GHB

GTPL4711

HSDB 6927

Hydroxyb

Hydroxybutyric acid monosodium salt

Hydroxybutyric acid-

HYDROXYBUTYRICACID

Juice

Liquid Ecstasy

LMFA01050006

LP090865

LS-46312

NCGC00247714-01

NSC84223

oxy-n-butyric acid

Oxybate

Oxybate sodium

PDSP1_000342

PDSP2_000340

SBI-0206686.P002

SCHEMBL10786

SHB

SJZRECIVHVDYJC-UHFFFAOYSA-N

Sodium .gamma.-hydroxybutyrate

Sodium .gamma.-oxybutyrate

Sodium gamma-oxybutyrate

Sodium Oxybate (4-hydroxybutanoic acid)

Somsanit

UNII-30IW36W5B2

utyric acid monosodium salt

WY 3478

WY-3478

Xyrem (TN)

ZINC1532805

US Patents and Regulatory Information for XYREM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Jazz Pharms	XYREM	sodium oxybate	SOLUTION;ORAL	021196-001	Jul 17, 2002	AA	RX	Yes	Yes
Jazz Pharms	XYREM	sodium oxybate	SOLUTION;ORAL	021196-001	Jul 17, 2002	AA	RX	Yes	Yes
Jazz Pharms	XYREM	sodium oxybate	SOLUTION;ORAL	021196-001	Jul 17, 2002	AA	RX	Yes	Yes			Y
Jazz Pharms	XYREM	sodium oxybate	SOLUTION;ORAL	021196-001	Jul 17, 2002	AA	RX	Yes	Yes
Jazz Pharms	XYREM	sodium oxybate	SOLUTION;ORAL	021196-001	Jul 17, 2002	AA	RX	Yes	Yes
Jazz Pharms	XYREM	sodium oxybate	SOLUTION;ORAL	021196-001	Jul 17, 2002	AA	RX	Yes	Yes			Y
Jazz Pharms	XYREM	sodium oxybate	SOLUTION;ORAL	021196-001	Jul 17, 2002	AA	RX	Yes	Yes			Y

Paragraph IV (Patent) Challenges for XYREM

Drugname	Dosage	Strength	RLD	Date
	Oral Solution	500 mg/mL

International Patents for XYREM

Country	Document Number	Estimated Expiration
Japan	2002533388
European Patent Office	2961399
World Intellectual Property Organization (WIPO)	2014134380
Taiwan	201511752
Spain	2193777
Austria	238783
Canada	2355293

Supplementary Protection Certificates for XYREM

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2015 00014	Denmark		PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150115
C/GB07/011	United Kingdom		PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003
C0108	Belgium		PRODUCT NAME: MANGAFODIPIR TRISODIUM (ANHYDROUS) CORRESP. MANGAFODIPIR; REGISTRATION NO/DATE: EU/1/97/040/001 19970522
C/GB00/021	United Kingdom		PRODUCT NAME: (1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE)BIS(PHOSPHONIC ACID) "RESIDRONATE" AND SALTS THEREOF, ESPECIALLY THE SODIUM SALT; REGISTERED: SE 15296 19991007; SE 15297 19991007; UK PL 00364/0070 20000316
C0021	France		PRODUCT NAME: PEGAPTANIB SODIUM; REGISTRATION NO/DATE: EU/1/05/325/001 20060131
C0005	Belgium		PRODUCT NAME: FOSPHENYTOIN DISODIUM; NAT. REGISTRATION NO/DATE: NL 23 613 19980806; FIRST REGISTRATION: GB - PL 000 19/0157 19980204
99C0030	Belgium		PRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508